Kyowa Kirin takes tivantinib into Asian Phase III trial for lung cancer
This article was originally published in Scrip
Executive Summary
Regional licensee Kyowa Hakko Kirin has begun an Asian Phase III clinical trial with ArQule's lead molecule tivantinib (ARQ 197), for the non-first-line treatment of non-small cell lung cancer (NSCLC).